Literature DB >> 28722313

Cellular glycosylation senses metabolic changes and modulates cell plasticity during epithelial to mesenchymal transition.

Patricia Carvalho-Cruz1, Frederico Alisson-Silva1, Adriane R Todeschini1, Wagner B Dias1.   

Abstract

Epithelial to mesenchymal transition (EMT) is a developmental program reactivated by tumor cells that leads to the switch from epithelial to mesenchymal phenotype. During EMT, cells are transcriptionally regulated to decrease E-cadherin expression while expressing mesenchymal markers such as vimentin, fibronectin, and N-cadherin. Growing body of evidences suggest that cells engaged in EMT undergo a metabolic reprograming process, redirecting glucose flux toward hexosamine biosynthesis pathway (HBP), which fuels aberrant glycosylation patterns that are extensively observed in cancer cells. HBP depends on nutrient availability to produce its end product UDP-GlcNAc, and for this reason is considered a metabolic sensor pathway. UDP-GlcNAc is the substrate used for the synthesis of major types of glycosylation, including O-GlcNAc and cell surface glycans. In general, the rate limiting enzyme of HBP, GFAT, is overexpressed in many cancer types that present EMT features as well as aberrant glycosylation. Moreover, altered levels of O-GlcNAcylation can modulate cell morphology and favor EMT. In this review, we summarize some of the current knowledge that correlates glucose metabolism, aberrant glycosylation and hyper O-GlcNAcylation supported by HBP that leads to EMT activation. Developmental Dynamics 247:481-491, 2018.
© 2017 Wiley Periodicals, Inc. © 2017 Wiley Periodicals, Inc.

Entities:  

Keywords:  O-GlcNAc; cancer; epithelial mesenchymal transition; glucose metabolism; glycosylation; hexosamine biosynthetic pathway

Mesh:

Substances:

Year:  2017        PMID: 28722313     DOI: 10.1002/dvdy.24553

Source DB:  PubMed          Journal:  Dev Dyn        ISSN: 1058-8388            Impact factor:   3.780


  19 in total

Review 1.  O-GlcNAc in cancer: An Oncometabolism-fueled vicious cycle.

Authors:  John A Hanover; Weiping Chen; Michelle R Bond
Journal:  J Bioenerg Biomembr       Date:  2018-03-29       Impact factor: 2.945

2.  Hexosamine pathway regulates StarD7 expression in JEG-3 cells.

Authors:  Jésica Flores-Martín; Luciana Reyna; Mariano Cruz Del Puerto; María L Rojas; Graciela M Panzetta-Dutari; Susana Genti-Raimondi
Journal:  Mol Biol Rep       Date:  2018-10-12       Impact factor: 2.316

Review 3.  Hyperglycemia and aberrant O-GlcNAcylation: contributions to tumor progression.

Authors:  Andréia Vasconcelos-Dos-Santos; Rafaela Muniz de Queiroz; Bruno da Costa Rodrigues; Adriane R Todeschini; Wagner B Dias
Journal:  J Bioenerg Biomembr       Date:  2018-01-11       Impact factor: 2.945

4.  Resistance to cisplatin in human lung adenocarcinoma cells: effects on the glycophenotype and epithelial to mesenchymal transition markers.

Authors:  Leonardo Marques da Fonseca; Vanessa Amil da Silva; Kelli Monteiro da Costa; Jhenifer Santos Dos Reis; José Osvaldo Previato; Lucia Mendonça Previato; Leonardo Freire-de-Lima
Journal:  Glycoconj J       Date:  2022-02-14       Impact factor: 2.916

Review 5.  O-GlcNAcylation regulation of cellular signaling in cancer.

Authors:  Lorela Ciraku; Emily M Esquea; Mauricio J Reginato
Journal:  Cell Signal       Date:  2021-11-17       Impact factor: 4.315

Review 6.  Emerging roles of N-linked glycosylation in brain physiology and disorders.

Authors:  Lindsey R Conroy; Tara R Hawkinson; Lyndsay E A Young; Matthew S Gentry; Ramon C Sun
Journal:  Trends Endocrinol Metab       Date:  2021-10-29       Impact factor: 10.586

7.  MicroRNA-206 regulates the epithelial-mesenchymal transition and inhibits the invasion and metastasis of prostate cancer cells by targeting Annexin A2.

Authors:  Ning Yang; Ling Wang; Jun Liu; Li Liu; Jiangbo Huang; Xian Chen; Zhigang Luo
Journal:  Oncol Lett       Date:  2018-03-30       Impact factor: 2.967

Review 8.  Fueling the fire: emerging role of the hexosamine biosynthetic pathway in cancer.

Authors:  Neha M Akella; Lorela Ciraku; Mauricio J Reginato
Journal:  BMC Biol       Date:  2019-07-04       Impact factor: 7.431

Review 9.  Drug resistance related to aberrant glycosylation in colorectal cancer.

Authors:  Ninon Very; Tony Lefebvre; Ikram El Yazidi-Belkoura
Journal:  Oncotarget       Date:  2017-11-03

Review 10.  A non-proliferative role of pyrimidine metabolism in cancer.

Authors:  Aarif Siddiqui; Paolo Ceppi
Journal:  Mol Metab       Date:  2020-02-13       Impact factor: 7.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.